Insider Selling: Kiniksa Pharmaceuticals International (NASDAQ:KNSA) COO Sells $514,262.80 in Stock

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) COO Eben Tessari sold 12,470 shares of Kiniksa Pharmaceuticals International stock in a transaction that occurred on Monday, November 17th. The shares were sold at an average price of $41.24, for a total value of $514,262.80. Following the sale, the chief operating officer directly owned 22,714 shares in the company, valued at $936,725.36. The trade was a 35.44% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link.

Eben Tessari also recently made the following trade(s):

• On Tuesday, October 14th, Eben Tessari sold 12,368 shares of Kiniksa Pharmaceuticals International stock. The shares were sold at an average price of $37.67, for a total value of $465,902.56.
• On Monday, September 29th, Eben Tessari sold 42,000 shares of Kiniksa Pharmaceuticals International stock. The shares were sold at an average price of $38.33, for a total value of $1,609,860.00.
• On Monday, September 15th, Eben Tessari sold 16,400 shares of Kiniksa Pharmaceuticals International stock. The stock was sold at an average price of $36.46, for a total value of $597,944.00.
• On Thursday, September 4th, Eben Tessari sold 85,271 shares of Kiniksa Pharmaceuticals International stock. The shares were sold at an average price of $35.52, for a total value of $3,028,825.92.
• On Friday, September 5th, Eben Tessari sold 13,389 shares of Kiniksa Pharmaceuticals International stock. The shares were sold at an average price of $35.66, for a total transaction of $477,451.74.
• On Wednesday, September 3rd, Eben Tessari sold 15,091 shares of Kiniksa Pharmaceuticals International stock. The stock was sold at an average price of $35.50, for a total transaction of $535,730.50.

Kiniksa Pharmaceuticals International Stock Up 0.2%

Shares of Kiniksa Pharmaceuticals International stock opened at $41.58 on Friday. Kiniksa Pharmaceuticals International, plc has a 12-month low of $17.82 and a 12-month high of $42.93. The stock has a market capitalization of $3.15 billion, a P/E ratio of 92.40 and a beta of 0.16. The company has a 50-day simple moving average of $38.43 and a 200 day simple moving average of $32.86.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last released its quarterly earnings results on Tuesday, October 28th. The company reported $0.23 EPS for the quarter, missing analysts’ consensus estimates of $0.31 by ($0.08). The firm had revenue of $180.86 million during the quarter, compared to analyst estimates of $166.64 million. Kiniksa Pharmaceuticals International had a net margin of 6.01% and a return on equity of 7.46%. Kiniksa Pharmaceuticals International’s quarterly revenue was up 61.2% on a year-over-year basis. During the same quarter last year, the firm earned ($0.18) earnings per share. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. On average, equities analysts anticipate that Kiniksa Pharmaceuticals International, plc will post -0.55 earnings per share for the current year.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals International

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Deutsche Bank AG grew its position in shares of Kiniksa Pharmaceuticals International by 177.1% during the 1st quarter. Deutsche Bank AG now owns 394,522 shares of the company’s stock worth $8,762,000 after buying an additional 252,125 shares during the period. Victory Capital Management Inc. bought a new position in Kiniksa Pharmaceuticals International during the 1st quarter worth approximately $1,184,000. Invesco Ltd. boosted its stake in Kiniksa Pharmaceuticals International by 137.4% during the 1st quarter. Invesco Ltd. now owns 33,492 shares of the company’s stock worth $744,000 after acquiring an additional 19,384 shares during the last quarter. BIT Capital GmbH acquired a new position in Kiniksa Pharmaceuticals International during the first quarter valued at approximately $264,000. Finally, Savant Capital LLC bought a new stake in Kiniksa Pharmaceuticals International in the second quarter valued at approximately $398,000. Institutional investors own 53.95% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the company. Weiss Ratings restated a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a research report on Wednesday, October 8th. Zacks Research cut Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “hold” rating in a report on Monday, October 6th. TD Cowen initiated coverage on Kiniksa Pharmaceuticals International in a research note on Monday, September 29th. They issued a “buy” rating and a $60.00 target price for the company. Wall Street Zen cut Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a report on Sunday, November 2nd. Finally, The Goldman Sachs Group increased their price objective on shares of Kiniksa Pharmaceuticals International from $45.00 to $55.00 and gave the stock a “buy” rating in a report on Wednesday, October 29th. Six investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $52.00.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.